Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year historical trend showing revenue and diluted EPS
Sequent Scientific's revenue grew 12.4% YoY in FY2025, with EPS growing 159.0%, solid top-line and bottom-line growth.
In FY 2025, Sequent Scientific's revenue grew by 12.4% year-over-year, while EPS grew by 159.0%. Revenue Growth: Shows Sequent Scientific's top-line expansion over time. Consistent revenue growth indicates market share gains, successful product launches, or pricing power. Look for steady upward trends rather than erratic spikes.
EPS Growth: Earnings Per Share growth measures profitability on a per-share basis. Growing EPS faster than revenue indicates improving profit margins and operational efficiency. The ideal scenario is both metrics growing together at healthy rates.
The Compound Annual Growth Rate shows the mean annual growth rate over specified time periods.
| METRIC | 1-YEAR CAGR | 5-YEAR CAGR | 10-YEAR CAGR |
|---|---|---|---|
|
Revenue
|
+12.4% | Upgrade | Upgrade |
|
Income
|
N/A | Upgrade | Upgrade |
|
EPS
|
N/A | Upgrade | Upgrade |
• CAGR calculations exclude periods with negative starting values or where values cross from positive to negative
• Green indicates positive growth, red indicates decline
Sequent Scientific's 10-year revenue CAGR of 13.3% reflects healthy long-term growth, however EPS CAGR is unavailable due to negative or inconsistent earnings over this period.
CAGR smooths out year-to-year volatility to show the steady annual growth rate over a period. 1-year captures recent momentum, 5-year reveals business cycle performance, and 10-year reflects durable competitive advantages.
Revenue CAGR above 15%, and EPS CAGR above 20% are generally considered excellent. Compare across all three periods and with industry peers for context.
Trend showing Sequent Scientific's revenue alongside key operational metrics
This chart is available with a paid plan. Get deeper insights into company fundamentals with full access to all charts and metrics.
Account Receivables: Money owed to Sequent Scientific by customers for goods or services delivered. Rising receivables relative to revenue may indicate collection issues or aggressive revenue recognition. Ideally, receivables should grow proportionally with revenue.
Inventories: Value of raw materials, work-in-progress, and finished goods. High inventory levels relative to revenue may suggest slow-moving stock or overproduction. Low inventory with rising revenue indicates efficient inventory management and strong demand.
Year-over-year growth in retained earnings showing Sequent Scientific's profit accumulation
Sequent Scientific's retained earnings grew 7.9% YoY in FY2025.
Over 2 years (FY2024–FY2025), retained earnings grew by 7.9%, from 6.07B to 6.54B.
In FY 2025, Sequent Scientific's retained earnings grew by 7.9% year-over-year. What are Retained Earnings: Retained earnings represent the cumulative net income that Sequent Scientific has retained, rather than distributed to shareholders as dividends. It reflects Sequent Scientific's ability to reinvest profits back into the business for growth, debt reduction, or other purposes.
Growth Interpretation: Consistent growth in retained earnings indicates strong profitability and effective capital allocation. Negative growth may signal losses, high dividend payouts, or share buybacks. Compare with revenue and net income growth to assess overall financial health.
Year-over-year growth in dividend per share showing Sequent Scientific's dividend payout trend
Sequent Scientific did not pay a dividend in FY 2025. What is DPS: Dividend Per Share (DPS) represents the total dividends paid out to shareholders divided by the number of outstanding shares. It indicates how much cash return investors receive for each share they own.
Growth Interpretation: Consistent DPS growth indicates management's confidence in future earnings and commitment to rewarding shareholders. Companies with steady dividend growth are often financially stable and mature. Compare with earnings growth to assess dividend sustainability.
Efficiency metric showing average days to collect payment from customers
This chart is available with a paid plan. Get deeper insights into company fundamentals with full access to all charts and metrics.
What is DSO: Days Sales Outstanding measures the average number of days it takes Sequent Scientific to collect payment after making a sale. Formula: (Account Receivables / Revenue) × 365. Lower DSO indicates faster cash collection and better working capital management.
Industry Context: DSO varies by industry. B2B companies typically have 30-60 days DSO, while B2C companies often have lower DSO. Compare with industry peers and payment terms offered to customers.
Interpretation: Increasing DSO may indicate collection problems, aggressive revenue recognition, or relaxed credit terms. Decreasing DSO suggests improving collection efficiency or stricter credit policies. Sudden spikes warrant investigation into customer creditworthiness or sales quality.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025